Fulgent Genetics, Inc. (FLGT)
- Previous Close
20.64 - Open
20.51 - Bid 20.72 x 200
- Ask 20.80 x 100
- Day's Range
20.42 - 20.77 - 52 Week Range
19.88 - 44.09 - Volume
149,074 - Avg. Volume
215,217 - Market Cap (intraday)
620.14M - Beta (5Y Monthly) 1.42
- PE Ratio (TTM)
-- - EPS (TTM)
-5.63 - Earnings Date May 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
26.67
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
www.fulgentgenetics.com1,184
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: FLGT
Performance Overview: FLGT
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FLGT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FLGT
Valuation Measures
Market Cap
617.15M
Enterprise Value
208.25M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.13
Price/Book (mrq)
0.54
Enterprise Value/Revenue
0.72
Enterprise Value/EBITDA
-4.24
Financial Highlights
Profitability and Income Statement
Profit Margin
-58.03%
Return on Assets (ttm)
-3.47%
Return on Equity (ttm)
-14.58%
Revenue (ttm)
289.21M
Net Income Avi to Common (ttm)
-167.82M
Diluted EPS (ttm)
-5.63
Balance Sheet and Cash Flow
Total Cash (mrq)
424.15M
Total Debt/Equity (mrq)
1.20%
Levered Free Cash Flow (ttm)
26.29M
Research Analysis: FLGT
Company Insights: FLGT
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: FLGT
FLGT: What does Argus have to say about FLGT?
FULGENT GENETICS INC has an Investment Rating of SELL; a target price of $17.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetFLGT: What does Argus have to say about FLGT?
FULGENT GENETICS INC has an Investment Rating of SELL; a target price of $17.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetFLGT: What does Argus have to say about FLGT?
FULGENT GENETICS INC has an Investment Rating of SELL; a target price of $17.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetFLGT: What does Argus have to say about FLGT?
FULGENT GENETICS INC has an Investment Rating of SELL; a target price of $17.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice Target